2006•Unpublished venueRequires access

Expression of wilms tumor gene(WT1) in leukemia patients and its clinical significance

Shi Lin-x

Open publisher page 0 citations

Abstract

Objective To evaluate the expression of WT1 gene in leukemia patients and its clinical implication. Methods Nest RT-PCR technique was applied to examine WT1 gene expression in 50 patients with leukemia. Results The WT1 mRNA positive rates in acute myeloid leukemias and lymphoblastic leukemias were 77.3% (17/22) and 54.5%(6/11) . In chronic myeloid leukemia, WT1 mRNA was undetectable at chronic phase ; but was revealed in 5 of 9 patients at blast crisis (55.6 %). The rate of remission in the patients positive for WT1 was lower than in those negative for WT1 (31.3 % vs 69.2 %, P 0.05). Conclusion The WT1 was highly expressed in the majority of the patients with leukemia and thus was involved in human leukemogenesis. It indicated WT1 could be a new prognostic factor and a panleukemia marker for the detection of MRD.

About this research paper

What this paper is about

Objective To evaluate the expression of WT1 gene in leukemia patients and its clinical implication. Methods Nest RT-PCR technique was applied to examine WT1 gene expression in 50 patients with leukemia. Results The WT1 mRNA positive rates in acute myeloid leukemias and lymphoblastic leukemias were 77.3% (17/22) and 54.5%(6/11) . In chronic myeloid leukemia, WT1 mRNA was undetectable at chronic phase ; but was revealed in 5 of 9 patients at blast crisis (55.6 %). The rate of remission in the patients positive for WT1 was lower than in those negative for WT1 (31.3 % vs 69.2 %, P 0.05). Conclusion The WT1 was highly expressed in the majority of the patients with leukemia and thus was involved in human leukemogenesis. It indicated WT1 could be a new prognostic factor and a panleukemia marker for the detection of MRD.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To evaluate the expression of WT1 gene in leukemia patients and its clinical implication. Methods Nest RT-PCR technique was applied to examine WT1 gene expression in 50 patients with leukemia. Results The WT1 mRNA positive rates in acute myeloid leukemias and lymphoblastic leukemias were 77.3% (17/22) and 54.5%(6/11) . In chronic myeloid leukemia, WT1 mRNA was undetectable at chronic phase ; but was revealed in 5 of 9 patients at blast crisis (55.6 %). The rate of remission in the patients positive for WT1 was lower than in those negative for WT1 (31.3 % vs 69.2 %, P 0.05). Conclusion The WT1 was highly expressed in the majority of the patients with leukemia and thus was involved in human leukemogenesis. It indicated WT1 could be a new prognostic factor and a panleukemia marker for the detection of MRD.

Key concepts: Myeloid leukemia, Wilms' tumor, Leukemia, Cancer research, Clinical significance, Gene, Medicine, Internal medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
Expression of wilms tumor gene(WT1) in leukemia patients and its clinical significance — Research Paper | ScholarLens